trending Market Intelligence /marketintelligence/en/news-insights/trending/hxR1Qy7oblp6HJKSjt03vA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Orexigen prevails in patent litigation against Teva unit

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Orexigen prevails in patent litigation against Teva unit

Orexigen Therapeutics Inc.'s weight-loss therapy Contrave will continue to have market exclusivity after a U.S. court favored the company in its patent litigation lawsuit against Actavis Laboratories FL Inc.

The U.S. District Court for the District of Delaware upheld the validity of all the patents involved in the case, with exclusivity through 2030.

Actavis Laboratories, a unit of Teva Pharmaceutical Industries Ltd., was looking to market a generic version of the drug.